Focus on HIV Care

Back to articles

Stepped-dose efavirenz reduces neuropsychiatric events


Results from a randomized, double-blind, controlled trial showed that initiating efavirenz (Sustiva— Bristol-Myers Squibb) in patients with HIV-1 infection using a stepwise dose schedule over a 2-week period reduced the incidence and intensity of neuropsychiatric adverse events without compromising virologic efficacy.